Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | FAAH | O00519 | 7/20 | 0.43 |
| ▸ | MGLL | Q99685 | 7/20 | 0.43 |
| ▸ | APAF1 | O14727 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL406638 | 0.76 | SLC9A1 (0.47) | HSD17B10APAF1POLBGAACYP2C9 | |
| SCHEMBL4752313 | 0.76 | HSD17B10 (0.50) | HSD17B10MGLLPOLBRAB9ANPC1 | |
| SCHEMBL4749932 | 0.76 | KMT2A (0.48) | HSD17B10HTTAPAF1POLB | |
| SCHEMBL25413984 | 0.75 | CHRM2 (0.46) | HSD17B10HTTFAAHMGLLPOLB | |
| SCHEMBL5790948 | 0.72 | POLB (0.57) | HSD17B10APAF1POLBGAACYP2C19 | |
| SCHEMBL25414963 | 0.72 | MEN1 (0.43) | HSD17B10HTTFAAHMGLLPOLB | |
| SCHEMBL14507096 | 0.72 | FAAH (0.48) | HTTFAAHMGLLPOLB | |
| SCHEMBL31024024 | 0.71 | FAAH (0.53) | HSD17B10HTTFAAHMGLLAPAF1 | |
| SCHEMBL1866263 | 0.71 | SLC9A1 (0.52) | HSD17B10APAF1POLBGAACYP2C9 | |
| SCHEMBL7377982 | 0.71 | SLC9A1 (0.52) | HSD17B10APAF1POLBGAACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | HSD17B10 1017/4885HTT 4390/4885FAAH 2632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.